ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
  • Abstract Number: 0310
    I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
  • Abstract Number: 2425
    Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial
  • Abstract Number: 1823
    Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts
  • Abstract Number: 0284
    Identification of Calcium Pyrophosphate Deposition Using Ultrasonography in Patients with a Suspected Diagnosis of Seronegative Rheumatoid Arthritis
  • Abstract Number: 2418
    Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 1993
    Identification of Elevated Soluble Factors in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Their Association with Severity and Persistence
  • Abstract Number: 1807
    Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus
  • Abstract Number: 0896
    Identification of Immune Pathways Regulated by a Non-Coding Variant at DNASE1L3/PXK/PDHB
  • Abstract Number: 2630
    Identification of Molecular Biomarkers for Sjögren’s Disease Stratification via a Deep Learning Foundation Model Dedicated to Immune-Mediated and Inflammatory Disease
  • Abstract Number: 2391
    Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
  • Abstract Number: 0383
    Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State
  • Abstract Number: 1711
    Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration
  • Abstract Number: 0887
    Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort
  • Abstract Number: 0705
    Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis
  • Abstract Number: 1866
    Identification of Sjögren’s Disease-Associated CD4+ T Cell Receptor (TCR) Motifs and Repertoire Landscape Through TCR Deep Sequencing
  • Abstract Number: 1664
    Identification of Spatial Determinants of Treatment Response in Rheumatoid Arthritis Synovia
  • Abstract Number: 2641
    Identification of Systemic Sclerosis Intrinsic Subtypes in the ASSET Clinical Trial Using PBC Gene Expression
  • Abstract Number: 2211
    Identifying Clinical Predictors of Difficult-to-Treat Rheumatoid Arthritis Using Machine Learning-based Techniques
  • Abstract Number: 1971
    Identifying Educational Opportunities Through Examination of Referrals to Rheumatology Musculoskeletal US Clinic
  • Abstract Number: 2626
    Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion
  • Abstract Number: 1042
    Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study
  • Abstract Number: 0909
    Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics
  • Abstract Number: 0353
    Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
  • Abstract Number: 2196
    Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings
  • Abstract Number: 2642
    Identifying Systemic Sclerosis Molecular Subtypes by Their Cellular Signature – Deconvoluting the Puzzle
  • Abstract Number: 0328
    IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
  • Abstract Number: 1658
    IGF1 Drives Wnt-induced Joint Damage and Is a Therapeutic Target for Osteoarthritis
  • Abstract Number: 1687
    IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases
  • Abstract Number: 2507
    IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil
  • Abstract Number: 0106
    IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS
  • Abstract Number: 2119
    IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures
  • Abstract Number: 0267
    IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis
  • Abstract Number: 1650
    IL-33 Expands Plasma Cells, Disrupts Germinal Centers and Increases Autoantibody Production
  • Abstract Number: 0231
    Imaging Characteristics and Demographic Variations in Patients with Axial Spondylarthritis, Axial Psoriatic Arthritis, and Inflammatory Bowel Disease-Related Arthritis with Axial Involvement: Insights from a Single Center at Cleveland Clinic Abu Dhabi
  • Abstract Number: 1983
    Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
  • Abstract Number: 0473
    Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology
  • Abstract Number: 1833
    Immune Complexes of Antibodies Directed to Angiotensin Receptor type-1 and Extracellular Vesicles Are Unique Modulators Contributing to Systemic Sclerosis
  • Abstract Number: 1795
    Immune Complexes-Mediated Activation of Neutrophils in Systemic Lupus Erythematosus Is Dependent on RNA Recognition by TLR8
  • Abstract Number: 1843
    Immune Responses to Herpes Zoster Vaccine Responses in Rheumatic Patients on JAK Inhibitors: Insights in Humoral and Cellular Response
  • Abstract Number: 1008
    Immune Responses to Infection and Autoimmune Diseases in the UK Biobank
  • Abstract Number: 0950
    Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde (MAA) Modified Vimentin Induces Fibrotic Lung Changes
  • Abstract Number: 0923
    Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde Modified Vimentin Induces Post-Translational Protein Modifications and Extracellular Matrix Deposition in Heart Tissues
  • Abstract Number: 1204
    Immunobased Profiling of Knee Osteoarthritis Patients to Predict Response to Regenerative Treatment with Autologous Blood-derivative Platelet-Rich Plasma Injection
  • Abstract Number: 2201
    Immunodeficiency-Related Monogenic Autoinflammatory Diseases; Expanding Spectrum of Immunodysregulation Disorders
  • Abstract Number: 1009
    Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept
  • Abstract Number: 1657
    Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis
  • Abstract Number: 0151
    Immunoproteomic Profiling of Antibodies in Autoimmune Diseases
  • Abstract Number: 1514
    Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
  • Abstract Number: 2266
    Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis
  • Abstract Number: 1038
    IMPACT (Impact of eMbedded Pharmacists in an Academic Center sTudy)
  • Abstract Number: 1035
    Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors
  • Abstract Number: 1032
    Impact of a Coordinated Care Model for Addressing Rheumatoid Arthritis and Associated Comorbidities
  • Abstract Number: 0596
    Impact of a Multidisciplinary Rheumatology-Dermatology-Gastroenterology Center in the Management of Patients with Psoriatic Arthritis: Analysis of the First 5-years of Implementation
  • Abstract Number: 1510
    Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort
  • Abstract Number: 2005
    Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
  • Abstract Number: 0412
    Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
  • Abstract Number: 2369
    Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis
  • Abstract Number: 0631
    Impact of Baseline Proteinuria Level on Long-term Outcomes in Lupus Nephritis
  • Abstract Number: 2209
    Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
  • Abstract Number: 1146
    Impact of COVID-19 on Myositis Testing Trends
  • Abstract Number: 1437
    Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
  • Abstract Number: 1124
    Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids
  • Abstract Number: 2148
    Impact of Hip Fractures in the Elderly Population: Functional Status, Readmission, and One-Year Mortality
  • Abstract Number: 0664
    Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors
  • Abstract Number: 2429
    Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study
  • Abstract Number: 1319
    Impact of Illness Cognition and Self-Esteem on Quality of Life in Reproductive-Age Women with Autoimmune Rheumatic Diseases
  • Abstract Number: 2144
    Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
  • Abstract Number: 1582
    Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
  • Abstract Number: 2653
    Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
  • Abstract Number: 0653
    Impact of Lupus Nephritis on Neuropsychiatric SLE Outcomes
  • Abstract Number: 1360
    Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
  • Abstract Number: 1611
    Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study
  • Abstract Number: 1198
    Impact of Metabolic Syndrome on Knee Osteoarthritis Severity and Progression: A PROCOAC Cohort Study
  • Abstract Number: 1903
    Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
  • Abstract Number: 2377
    Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY
  • Abstract Number: 2408
    Impact of Pain and Fatigue on Quality of Life Among Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1411
    Impact of Patient and Physician Alignment on Sjögren’s Disease Severity, a Real-World Survey on Patients’ Clinical Outcomes and Health-Related Quality of Life
  • Abstract Number: 0542
    Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
  • Abstract Number: 0543
    Impact of Peripheral Manifestations on Function, Health, and Work Productivity in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
  • Abstract Number: 0583
    Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
  • Abstract Number: 1055
    Impact of Provider Billing vs. Pharmacy Dispensation for Romosozumab Treatment Discontinuation Among U.S. Postmenopausal Women with Osteoporosis
  • Abstract Number: 1111
    Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism
  • Abstract Number: 0169
    Impact of Sense of Control Among People Living with SLE
  • Abstract Number: 0187
    Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
  • Abstract Number: 0848
    Impact of SGLT2i Initiation on the Need for Urate-Lowering Therapy and Colchicine Among Gout Patients with Type 2 Diabetes:Propensity-Score Matched, Active Comparator, New User Design Study
  • Abstract Number: 0236
    Impact of Socioeconomic Status on Infection-Related Hospitalization Risk in Patients with Systemic Autoimmune Diseases
  • Abstract Number: 1045
    Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
  • Abstract Number: 0720
    Impact of Systemic Vasculitides on Sexual Function: An Overlooked Aspect of Patient Care
  • Abstract Number: 0626
    Impact of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) in Systemic Lupus Erythematosus Patients from the Almenara Lupus Cohort
  • Abstract Number: 0349
    Impact of the Stanford University Chronic Pain Self-Management Education Program on Pain Severity, Pain Self-Efficacy, and Pain Disability in a Population with a High Prevalence of Arthritis
  • Abstract Number: 1522
    Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020
  • Abstract Number: 0051
    Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis
  • Abstract Number: 1047
    Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
  • Abstract Number: 1625
    Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis
  • Abstract Number: 0472
    Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
  • Abstract Number: 0046
    Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies
  • Abstract Number: 1949
    Implementation of Pharmacist-Led Comprehensive Medication Management for Puerto Ricans with Rheumatic Diseases
  • Abstract Number: 1275
    Implementing Integrated Mental Health Care in a Juvenile Myositis Clinic: A One-Year Review
  • Abstract Number: 1741
    Implementing Strengths-Based, Positive Approaches Within Rheumatology Fellowship Training: A Realist Evaluation of Appreciative Inquiry-Based Interventions
  • Abstract Number: 1647
    Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission
  • Abstract Number: 1168
    Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan
  • Abstract Number: 2455
    Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)
  • Abstract Number: 2207
    Improvement Across Physician and Patient Reported Outcome Measures over a 24 Months-time Period in the Juvenile Systemic Scleroderma Inception Cohort
  • Abstract Number: 2366
    Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
  • Abstract Number: 1543
    Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active Systemic Lupus Erythematosus
  • Abstract Number: 0355
    Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
  • Abstract Number: 0490
    Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality
  • Abstract Number: 0184
    Improving Age Disparities in Contraceptive Counseling in Women with Lupus: A Quality Improvement Initiative
  • Abstract Number: 0418
    Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice
  • Abstract Number: 1068
    Improving Health Numeracy Literacy in Pediatric Patients with SLE
  • Abstract Number: 1911
    Improving Healthcare Access in Underserved Brooklyn Communities: A Comprehensive Multispecialty Patient Navigator Program
  • Abstract Number: 1264
    Improving Mental Health Care for Youth with Juvenile Dermatomyositis Through Integration of Mental Health Screening into Pediatric Rheumatology Clinic
  • Abstract Number: 2529
    Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project
  • Abstract Number: 1021
    Improving Preoperative Osteoporosis Screening for Orthopedic Patients
  • Abstract Number: 0377
    Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis
  • Abstract Number: 1078
    Improving SLEDAI-2K Documentation for Childhood-Onset Systemic Lupus Erythematosus (cSLE) in a Pediatric Rheumatology Clinic Using Quality Improvement Methodology
  • Abstract Number: 1069
    Improving Triage Accuracy of Unclear Rheumatology Referrals: A Quality Improvement Study
  • Abstract Number: 1533
    Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
  • Abstract Number: 2432
    In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
  • Abstract Number: 1648
    In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells
  • Abstract Number: 1732
    In Vitro Screening of siRNAs Designed to Knockdown Interferon Beta as a Novel Therapeutic Approach for Treatment of Adult and Juvenile Dermatomyositis
  • Abstract Number: 0928
    In Vitro Study of Fibroblast-Like Synoviocytes and Macrophages-Like Synoviocytes Isolated from Rheumatoid Arthritis, Psoriatic Arthritis Patients and Healthy Subjects
  • Abstract Number: 1799
    In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
  • Abstract Number: 2662
    In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
  • Abstract Number: 0718
    Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic
  • Abstract Number: 1515
    Incidence and Predictors of Neuropsychiatric Lupus—a Contemporary Cohort Study Across the United States
  • Abstract Number: 2372
    Incidence and Predictors of Recurrent Pericarditis in Systemic Lupus Erythematosus
  • Abstract Number: 1455
    Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis
  • Abstract Number: 0724
    Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study
  • Abstract Number: 0859
    Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
  • Abstract Number: 1505
    Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
  • Abstract Number: 2568
    Incidence of First Fracture in RA Is Increasing Faster Than the General Population
  • Abstract Number: 1564
    Incidence of Posttraumatic Stress Disorder Secondary to the Diagnosis of Systemic Sclerosis
  • Abstract Number: 1519
    Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
  • Abstract Number: 0218
    Incidental Findings on Whole Body 18F-FDG PET/CT in a Rheumatoid Arthritis Clinical Trial Population
  • Abstract Number: 2397
    Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients
  • Abstract Number: 2070
    Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients
  • Abstract Number: 0957
    Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
  • Abstract Number: 0032
    Increased Expression of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues During the Early Evolution of Collagen-Induced Arthritis
  • Abstract Number: 2121
    Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study
  • Abstract Number: 1150
    Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies
  • Abstract Number: 1330
    Increased Levels of F-calprotectin in Patients with Early Rheumatoid Arthritis at Diagnosis
  • Abstract Number: 1153
    Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology
  • Abstract Number: 0954
    Increased Proliferating Natural Killer Cells Exhibit an Aberrant Pro-Inflammatory Gene Signature in Systemic Sclerosis Patients
  • Abstract Number: 2078
    Increased RAGE Expression in Myositis
  • Abstract Number: 2339
    Increased Risk of Psoriatic Arthritis in Patients with Familial Mediterranean Fever: A Population-Based Cohort Study
  • Abstract Number: 1024
    Increased Social Vulnerability Index Predicts Lower Likelihood of Remission in Rheumatoid Arthritis Patients
  • Abstract Number: 2385
    Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations
  • Abstract Number: 0464
    Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
  • Abstract Number: 1476
    Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis
  • Abstract Number: 2000
    Induction of Systemic Inflammatory Diseases with Dupilumab Therapy
  • Abstract Number: 2550
    Infiltrating and Resident Macrophages in Lupus Nephritis: Scar Associated Macrophage Phagocytic Dysfunction and Fibroblast Activation
  • Abstract Number: 0043
    Inflammatory and Angiogenic Serum Profile of Refractory Rheumatoid Arthritis
  • Abstract Number: 0396
    Inflammatory Markers of Autoimmune Uveitis in the Eye, Tears and Blood
  • Abstract Number: 0049
    Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis
  • Abstract Number: 0305
    Inflammatory T Cell Expansion in Yao Syndrome
  • Abstract Number: 0681
    Influence of Occupational Exposure to Pollutants on Clinical and Serological Phenotypes in Systemic Sclerosis
  • Abstract Number: 2341
    Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis
  • Abstract Number: 0955
    Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis
  • Abstract Number: 0078
    Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity
  • Abstract Number: 1801
    Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
  • Abstract Number: 1991
    Initial Corticosteroid Dosing and Effects on Disease Activity, Survival, and Tumor Progression in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
  • Abstract Number: 1067
    Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement
  • Abstract Number: 1239
    Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients
  • Abstract Number: 1064
    Inpatient and Outpatient Palliative Care Referral Practices for Patients with Rheumatic Disease: Retrospective Chart Review at a Single Academic Medical Center
  • Abstract Number: 1245
    Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative
  • Abstract Number: 0733
    Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
  • Abstract Number: 0466
    Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample
  • Abstract Number: 1978
    Insertional and Midportion Achilles Tendinopathy Have Differences in Presence of Calcifications and Neovascularization
  • Abstract Number: 0734
    Insights into Readmissions of ANCA-Vasculitis Patients: A Nationwide Analysis
  • Abstract Number: 1922
    Insights into Rheumatology Practice in Uganda
  • Abstract Number: 1819
    Insulin-like Growth Factor Binding Protein-7 (IGFBP7) Plays a Pathogenic Role in Dermal Fibrosis and Is Increased in Systemic Sclerosis
  • Abstract Number: 2643
    Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
  • Abstract Number: 0860
    Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases
  • Abstract Number: 0181
    Integrated Multidisciplinary Lupus Social Work Program to Manage Social Determinants of Health in SLE and Lupus Nephritis – Preliminary Results
  • Abstract Number: 2358
    Integration of Single-cell Multi-omics Profiling for Investigating Treatment Response to Tumor Necrosis Factor Alpha Inhibitors in Patients with Axial Spondyloarthritis
  • Abstract Number: 0271
    Intercritical Gout Represents a Systemic Inflammatory State
  • Abstract Number: 1952
    Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry
  • Abstract Number: 1347
    Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
  • Abstract Number: 2288
    Interferon Gamma Signaling Is Associated with Development of Extraglandular Manifestations in Sjögren’s Disease
  • Abstract Number: 0815
    Interferon-stimulated Gene Expression in Non-lesional Skin Is Similarly Elevated in Incomplete SLE and SLE
  • Abstract Number: 0666
    Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy
  • Abstract Number: 0901
    Intergenic Alu Elements Are Uniquely Expressed in Dermatomyositis and Correlate with Interferon Stimulated Genes
  • Abstract Number: 0308
    Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
  • Abstract Number: 1608
    Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes
  • Abstract Number: 2463
    Interstitial Lung Disease in Very Early Systemic Sclerosis – a Clinical and Radiological Characterization
  • Abstract Number: 1186
    Intra-articular Corticosteroid Injections for Knee Osteoarthritis: Does the Dose Matter?
  • Abstract Number: 2271
    Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial
  • Abstract Number: 0281
    Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
  • Abstract Number: 0121
    Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers
  • Abstract Number: 1626
    Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review
  • Abstract Number: 1804
    Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development
  • Abstract Number: 1258
    Investigating Factors Associated with Gaps in Care in Adolescents and Young Adults with Systemic Lupus
  • Abstract Number: 2441
    Investigating Kidney Disease Risks in Systemic Sclerosis (SSc) – Effects of Proton Pump Inhibitors (PPI): Retrospective Analysis
  • Abstract Number: 1329
    Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty
  • Abstract Number: 1107
    Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective
  • Abstract Number: 0813
    Investigating TASL, SLC15A4, & TLR7 Associated Risk SNPs in Systemic Lupus Erythematosus
  • Abstract Number: 0822
    Investigating the Association Between Alcohol Consumption and Spinal Radiographic Progression in Axial Spondyloarthritis: A Longitudinal Cohort Analysis over a Period of 6 Years
  • Abstract Number: 2319
    Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns
  • Abstract Number: 1282
    Investigating the Genetics of Depression and Anxiety in Children and Adolescents with and Without Systemic Lupus Erythematosus
  • Abstract Number: 0872
    Investigating the Natural Improvement of Rheumatoid Arthritis During Pregnancy
  • Abstract Number: 0880
    Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
  • Abstract Number: 0207
    Investigation of Delays in Cancer Screening in RA
  • Abstract Number: 0311
    Investigation of Sarcoidosis-associated Neuropathy: Challenges with Diagnosis of Small Fiber Neuropathy
  • Abstract Number: 1463
    Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
  • Abstract Number: 0945
    Involvement of Cellular Senescence in Rheumatoid Arthritis-associated Interstitial Lung Disease of SKG Mice
  • Abstract Number: PP04
    Involving Pediatric Patients in Their Own Care
  • Abstract Number: 0932
    IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
  • Abstract Number: 2029
    Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients from the JIR Cohort
  • Abstract Number: 1615
    Is Regular Vascular Imaging Scheduled Essential in the Follow-Up of Takayasu Arteritis? A Large-Scale Multicenter Cohort Study
  • Abstract Number: 0550
    Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study
  • Abstract Number: 1446
    Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters?
  • Abstract Number: 2378
    Is Urinary Protein-creatinine Relation Reliable for Diagnosis or Follow up of Lupus Nephritis?
  • Abstract Number: 0916
    Isocitrate Dehydrogenase 2 Mutations Are Associated with Autoimmune Rheumatologic Diseases in Chronic Myelomonocytic Leukemia
  • Abstract Number: 1164
    IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients
  • Abstract Number: 1902
    Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Jump to:  View All • a b c d e f g h [i] j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology